biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by cornpieon Sep 23, 2017 2:49pm

125 Views

Post# 26734692

RE:RE:New Directors

Stagliano, one of 2013's FierceTop Women in Biotech, said: As we evolve our business, the more options, the better and this includes future financings, partnering and investment in other programs. With the capital weve raised, we have the flexibility to consider those opportunities in the fullness of time, without being preoccupied with the current market environment......sounds like we have a winner here.

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages